Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.

"data availability statement the gwas summary statistics are available through the nhgri-ebi gwas catalogue under study accession numbers gcst90095054-gcst9009572. data availability statement the gwas summary statistics are available through the nhgri-ebi gwas catalogue under study accession numbers gcst90095054"

"CONFLICT OF INTEREST Timothy S. Maughan consults for AstraZeneca and receives personal fees from Pierre Fabre (IDMC services). Timothy S. Maughan received research funding from Merck KgAa and AstraZeneca. The institution where Timothy S. Maughan works receives funding from Bayer. David J. Kerr is a director of Oxford Cancer Biomarkers. All other authors have declared no conflicts of interest."

"Funding information This work was supported by Cardiff University School of Medicine (to KW), Tenovus Cancer Care (to JPC and CW), KFSHRC (to NAA) and Cancer Research UK (grant number C1298/A8362 to RSH). The COIN and COIN‐B trials were funded by Cancer Research UK, the Medical Research Council and an unrestricted educational grant from Merck‐Serono and were conducted with the support of the National Institute of Health Research Cancer Research Network. None of the sponsors played a role in the study design; the collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the article for publication."